Photo courtesy of M6 Global

For a large portion of his career, Mike Matranga worked as a Secret Service agent protecting the President and First Family all over the world.

He then moved to the Department of the Interior, specializing in domestic terrorism, when the 2018 shooting at Marjory Stoneman Douglas High School occurred. Only three months later, another school shooting happened in Santa Fe, Texas.

That's when Matranga received a phone call from a Texas superintendent, asking him to take his decades of security experience and training and develop a proactive school safety program — something that didn't yet exist. That comprehensive, holistic plan would go on to be ranked No. 1 in Texas and No. 5 in the nation.M6

Mike Matranga, M6 GlobalM6 Global's Mike Matranga.Photo courtesy of M6 Global

This led Matranga to found M6 Global, which today specializes not only in school safety plans but also programs for industrial and corporate settings and even major sporting events.

The team is comprised of current and former federal agents and security specialists, a psychiatrist, a leading emotional intelligence doctor, a former White House doctor, and emergency management experts. Together, they have more than 100 years combined experience in school safety, law enforcement, and national and global security.

And that's what's made Matranga's initiatives so successful: the people.

“Of all the measures and initiatives we implemented, the absolute most important thing we have are people who have the ability to make real change — which no camera system will provide," he says. "Simply teaching people how to identify pre-attack behavior, self-harm behavior, and a person in crisis will always be what is most important. Secondly, having the resources and courage to intervene once those things are identified will keep individuals off the path to violence. We must never discredit the human element.”

M6 Global also partners with ASAP Security Services in Houston to provide the most up-to-date technology and products, with everything from facial recognition software to cameras to threat detection software. It makes their services fully turn-key, and as Matranga says, "two brains are better than one."

Mike Matranga and President Joe Biden, M6 GlobalMike Matranga (left) with President Joe Biden.Photo courtesy of M6 Global

"At some point we have to realize that the law enforcement response that we adopted in the '80s is not working," he adds. "And it’s not just police — it’s the patterns and behaviors of people that will tell you there is a problem, so we need to shift from a reactive to a proactive mindset. We need to have actionable resources in place and a society that's better informed to recognize the signs before someone becomes a person in crisis."

To learn more about M6 Global and explore its services, visit here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”